Last edition
News about "Antengene Corporation"
Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval
Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.
Antengene Corporation | 26/08/2026 | By News Bureau
Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy
Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.
Antengene Corporation | 06/03/2026 | By News Bureau | 222
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy